Researchers analyzed three clinical trials to see if giving anti-EGFR drugs again could help patients with a specific type of advanced colorectal cancer. The patients had already received other treatments, and their cancer had a certain genetic profile (ctDNA RAS/BRAF wild type). The analysis included 320 patients total, comparing those who received the anti-EGFR rechallenge to those who received standard care.
The review found that patients who got the anti-EGFR drugs again were more likely to have their tumors shrink or stop growing. Their cancer also took longer to start progressing again compared to those on standard care. Importantly, the analysis did not find that this strategy helped patients live longer overall. Safety information from the trials was not reported in this review.
This is a careful look at early, phase II trials, which means the evidence is still developing. The main reason to be cautious is that improving survival is the ultimate goal, and that benefit was not seen here. Readers should understand this as a promising signal for a specific group of patients, but it is not yet a definitive treatment strategy. Doctors and patients will need results from larger, more advanced trials to make confident decisions.